ECU Logo
 




 


photo of Emmanuel Zervos

 

Emmanuel E. Zervos, M.D., FACS
Associate Professor of Surgery

 

Address:
East Carolina University Brody School of Medicine
600 Moye Boulevard
Greenville, NC 27834  
Office: 252-744-5418
Fax: 252-744-5777
Email:
Zervose@ecu.edu


Pending Appointment:  
July 2007
Professor and Chief
Division of Surgical Oncology
East Carolina University, Brody School of Medicine
Associate Director, Leo W. Jenkins Cancer Center

Current Appointment:  
July 2006- present:  
Associate Professor of Surgery with tenure, Department of Surgery, Division of General Surgery, University of South Florida

July 2001 – June 2006:
Assistant Professor of Surgery, Division of General Surgery
Department of Surgery, University of South Florida

July 2001 – present
Associate Professor
Department of Clinical Investigation, H. Lee Moffitt Cancer Center and     Research Institute, Tampa, FL

Education:             
September 1984- May 1988:  Bachelor of Arts - Economics, With Highest Distinction:  University of Michigan College of Literature, Arts and Sciences,  Ann Arbor, MI
August 1988 – May 1992:  Doctor of Medicine:  University of Michigan College of Medicine, Ann Arbor, MI
 
Professional Training:                        
July 1992- June 1993:  Internship – General Surgery:  University of Michigan Hospitals, Ann Arbor, MI
July 1993- June 1995:  Junior Surgical Resident – General Surgery:  University of South Florida Hospitals, Tampa, FL     
July 1995- June 1997: Fellowship in Surgical Research - University of South Florida, Tampa, FL
July 1997- June 1998: Senior Surgical Resident - University of South Florida, Tampa, FL
July 1998- June 1999:  Chief Resident in Surgery - University of South Florida, Tampa, FL
July 1999- June 2000:   Clinical  Surgical Oncology Fellow - Ohio State University, Columbus, OH
July 2000- June 2001:   Surgical Oncology Research Fellow - Division of Human Medical Genetics – laboratory of Albert delaChapelle, PhD, Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Board Certification:   
1993 National Board of Medical Examiners

1999 American Board of Surgery

Editorial Review:

Editorial Board:
Surgical Rounds

Refereee:
Journal of Surgical Research – 2003
British Journal of Cancer -  2005
Journal of Oncology – 2002
Frontiers in Bioscience – 2005
Digestive Diseases and Science – 2005
Journal of Surgical Oncology – 2005
Archives of Surgery -2006
Expert Opinion on Biological Therapy -2007
Journal of the American College of Surgeons - 2007

Associations:
American College of Surgeons, Fellow (ACS), 2001
International Hepatobiliary Association, (IHPBA), 2003
Association for Academic Surgery (AAS), 2003
Frederick A. Coller Surgical Society, 2000
Society of Surgical Oncology, 2003
Tampa Bay Surgical Society, 2001
Florida Surgical Society, 2001
American Association for Cancer Research, 2000
American Society of Clinical Oncology, 2000       Florida Chapter of the American College of Surgeons, 2001
Applications in process:
Society of University Surgeons 2008 (application submitted)
Southern Surgical Association
           
Licensure:  
State of Ohio
State of Florida

Achievement and Honors:

1984 Winner, The Grand Rapids Press Wonderland Writer’s       
Competition           
1984 Grand Rapids Ottawa Hills High School, Valedictorian     
1984  Regents Alumni Scholarship, University of Michigan
1984 Merit Scholarship, University of Michigan
1984    Foster Foundation Scholarship, Grand Rapids, MI
1984    Winchester Foundation Scholarship, Grand Rapids, MI
1984    American Hellenic Educational Progressive Association       
Scholarship
1984    Pancretan Association of America Scholarship
1988    B.A.University of Michigan College of Literature Science and      
Arts, “With Highest Distinction”  
1994 H. Quillian Jones Award, Best Resident Paper,  Florida Committee     
on Trauma   
1995 1st Place, Resident Research Competition, Florida Surgical Society    
1995 SSAT / Ross Resident Research Award
1996    Florida Committee on Trauma, Resident Paper Competition
Award, 1st Place  
1996 1st Place, Resident Research Competition, Florida Surgical Society
1997 1st Place, Physician’s in Training Paper  Competition Southern Medical Association  
1997 Watson Clinic Award - Best Research Presentation  USF Research
Day
1998 Frederick A. Coller Surgical Society, Coller Society Clinical
Tour
1998 Elected to Alpha Omega Alpha  Medical Honor Society
1999 Society of Abdominal Surgeons Resident Research Award
2000 Successful completion of American Board of Surgery Qualifying
Exam
2001 Scholarship Recipient American Association for Cancer Research           
Molecular Biology in Clinical Oncology, Aspen, CO July 2000
2002 Scholarship Recipient American Association of Clinical Oncology (ASCO)
–Methods in Clinical Cancer Research , Vail, CO
2001   Columbus Surgical Society: 1st Place Resident Paper Competition 
2001   American Society of Breast Surgeons:  Best Poster Presentation, La     
Jolla, CA May 2001
2001  Ohio State University: 1st Place – Resident Paper Competition –      
Mentor
2003   Association of VA Surgeons Best Scientific Presentation
2004   USF Research Day – Best Scientific Poster
2006 Bronze Medal Award Winner – Dean’s Leadership Council - University of South Florida
2007 Best Post-Graduate Research Presentation – USF Research Day 2007  

Primary Mentorship:
Academic: 
Sarah Cowgill, M.D. Masters Student in Clinical Research, University of South Florida K30 Master’s Program; Director: Ken Zuckerman, M.D.

Laboratory:
Nasreen A. Vohra, M.D., 2 years in Lab
Surgical Research Fellow, USF
 
Previous laboratory fellows:
 
Dana Osborne, M.D.,2004-2006 
General Surgery Resident USF
Application to surgical oncology
Fellowships in process

Brian A. Boe, MS, 2004-2005 
Medical Student Level II USF

Alan J. Durkin, M.D., 2002-2004 
Plastic Surgery Fellow - USF

Mark Bloomston, M.D., 2000-2002
Asistant Professor of Surgery,
The Ohio State University,
Division of Surgical Oncology

Publications  (hyperlinks to free online reprints in blue):  

1.  Zervos, E.  “War”, Wonderland Magazine, The Grand Rapids Press, June 3, 1984, pp. 9-10.

2.  Zervos, EE, Bass, SS, Robson MC, Rosemurgy, AS.  Fluconazole increases the bactericidal
     activity of neutrophils.  J Trauma 41:10-14, 1996.

3.  Zervos, EE, Fink, GW, Norman, JG, Robson, MC, Rosemurgy, AS.  Fluconazole increases the  bactericidal activity of neutrophils through non-cytokine mediated pathway. 
 J Trauma, 41: 465-70, 1996.

4.  Camps, MA, Zervos, EE, Goode, SE, Rosemurgy, AS.  Does inadequate weight loss following bariatric surgery predict staple line failure?  A prospective study.  Obesity Surgery, 6:330-5, 1996.

5.  Camps, MA, Zervos, EE, Goode, SE, Rosemurgy, AS.  Impact of bariatric surgery on body image perception and sexuality in morbidly obese patients and their partners.  Obesity Surgery, 6:356-60,1996.

6.   Rosemurgy, AS, Zervos, EE. Sweeney, JF, Djieu, JY.  Candida antigen titer dilution and death after injury.  Br J Surg, 84:771-774, 1997.

7.  Zervos, EE, McCormick, J, Goode, SE, Rosemurgy, AS.  Peritoneovenous shunts in patients with intractable ascites: palliation at what price?  Am. Surg, 63:157-62, 1997.

8.  Rosemurgy, AS,   Zervos, EE, Goode, SE, Black, TJ, Zwiebel, BR.  Differential effects on portal and effective hepatic blood flow: a comparison between TIPS and small diameter H-graft portacaval shunt.  Ann Surg, 225:601-8, 1997.

9. Zervos EE, Rosemurgy AS.  Small-diameter portocaval shunt vs. transjugular intrahepatic portosystemic shunt for portal hypertension.
Adv Surg. 1997;31:105-25.

10. Zervos, EE, Norman, JG, Gower, WR, Franz, MG, Rosemurgy, AS.  Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res, 69: 367-371, 1997.

11. Zervos, EE, Norman, JG, Salhab, C, Rosemurgy, AS.  Sublethal Hemorrhage Blunts the                                             
       Inflammatory Cytokine Response to Endotoxin in a Rat Model.  J Trauma, 46: 145-149, 1999

12. Zervos, EE, Norman, JG, Carey, LC, Salhab, C, Rosemurgy, AS.  Conditioning to hemorrhagic shock improves survival and attenuates inflammatory cytokine gene induction in the lung, liver and spleen of rats.  Surg Forum, 48: 127-129, 1997.

13. Rosemurgy, AS, Bloomston, PM, Zervos, EE, Goode, SE, Pencev, D, Zweibel, BR, Black, TJ.  TIPS vs. H-graft portacaval shunt in the management of bleeding varices: a cost benefit analysis.  Surgery, 122:794-799, 1997.

14. Zervos, EE, Norman, JG, Carey, LC, Rosemurgy, AS.  Cytokine activation through sublethal hemorrhage is protective against early, lethal endotoxic challenge.  Arch Surg  132: 1216-1221, 1997.

15. Bloomston, PM, Zervos, EE, Goode, SE, Rosemurgy, AS.  Outcomes following bariatric surgery In super vs. Morbidly obese patients: Does weight matter?  Obesity Surg, 7: 414-419, 1997.

16.  Bloomston, PM, Zervos, EE, Powers, P, Rosemurgy, AS.  Vertical banded gastroplasty in a
 patient with multiple personalities: nuances and complexities of care.  Obesity Surg, 7:363-366, 1997.

17.  Zervos, EE, Goode SE, Rosemurgy, AS.  Immediate and long term portal hemodynamic
       consequences of the small diameter H-graft portacaval shunt.  J Surg Res, 74: 71-75, 1998.

18.  Zervos, EE, Goode SE, Rosemurgy, AS.  Small diameter H-graft portacaval shunt reduces portal pressure without compromising effective hepatic blood flow.  Amer Surg, 64:71-76, 1998.

19.  Denham, EW, Yang, JG, Fink, G, Zervos, EE, Norman, JG.   Pancreatic ascites as a  powerful inducer of inflammatory cytokines: the role of known vs unknown factors. Arch  Surg, 132: 1231- 1236, 1997.

20.  Rosemurgy, AS, Serafini, FS, Zervos, EE, Goode, SE.  Small Diameter H-graft portacaval   shunt:  excellent outcomes in more than 100 patients.  J Gastrointestinal  Surg, 2 (6): 585-591, 1998.

21.   Rosemurgy AS, Bloomston M, Zervos EE, Goode SE, Pencev D, Zweibel B, Black TJ.     Transjugular Intrahepatic Portosystemic Shunt versus H-Graft Portacaval Shunt in the    Management of Bleeding Varices:  A Cost-Benefit Analysis. Curr Surg 1998; 55: 171-2.

22.    Bloomston, M, Zervos, EE, Gonzalez, R, Albrink, M, Rosemurgy, AS.  Quality of life and                     
 antireflux medication use following laparoscopic Nissen fundoplication.  Amer Surg, 64: 509-514, 1998.

23.  Denham, D, Franz, MG, Zervos, EE, Gower W, Rosemurgy, AS, Norman JG.  Directed antisense therapy confirms the role of PKC-  in the tumorigenicity of pancreatic cancer.  Surgery 124: 218-224, 1998.

24.  Zervos, EE, Shafii, AE, Rosemurgy, AS.  Matrix metalloproteinase inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.  J Surg Res, 81:65-68, 1999.

25.  Zervos, EE, Shafii, AE, Haq, M, Rosemurgy, AS.  Matrix metalloproteinase inhibition supresses MMP-2 activity and activation of PANC-1 cells in vitro.  J Surg Res, 84:162-167, 1999.

26.  Zervos, EE, Franz, M, Shafii, AE, Salhab, K, Rosemurgy, AS.  Matrix metalloproteinase inhibition improves survival in an orthotopic model of human pancreatic cancer.  J Gastrointestinal Surgery, 4:614-619, 2000.

27.  Haq, M, Shafii, A, Zervos, EE, Rosemurgy, AS.  Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer.  Cancer Research,  60: 3207-3211; 2000.

28.  Zervos, EE, Rosemurgy, AS.  Management of Medically Refractory Ascites.  Abdominal Surgery, Fall 1999, pp 2-8.

29.  Zervos, EE, Saha, S, Hoshaw-Woodard, S, Wheatley, G, Burak, W.  Localizing the sentinel node outside of the specialty center: success of the lymphatic mapping course in disseminating new technology.  Ann Surg Onc.  8:7-12; 2001.

30.  Zervos, EE, Rosemurgy, AS.  Management of Medically Refractory Ascites: A Surgeon’s Guide. (review) Am J Surgery 2001; 181: 256-264.

31.  Zervos, EE, Burak, WE.  Lymphatic Mapping for Breast Cancer:  Experience at The Ohio State University.  Breast Cancer 7:195-200; 2000.

32.  Desai, D, Zervos, EE, Martin, EW.  Positron Emission Tomography Affects Surgical Management in Recurrent Colorectal Cancer Patients.  Ann Surg Onc 2003; 10(1):59-64.

33.  Serafini FM, Bloomston, MP, Zervos, EE, et al.  Laparoscopic Revision of Failed Anti-Reflux Operations.  J Surg Res 2001; 95:13-18.

34.  Zervos EE, Desai DC, DePalatis LR, Soble D, Martin EW.  FDG-Pet Guided Surgery for Recurrent Colorectal Cancer: A Feasibility Study.  J Surg. Res 2001; 97:9-13.

35.  Burak WE, Holleneck ST, Zervos EE, et al.  Physiologic and socioeconomic consequences of breast cancer surgery:  a comparison between sentinel lymph node biopsy and axillary lymph node dissection.  American Journal of Surgery 2002; 182:316-320.

36.  Zervos EE, Badgwell B, Burak WB, Arnold MW, Martin EW.  FDG-PET as an adjunct to CEA in the management of colorectal cancer patients with rising CEA and non-diagnostic radiologic workup.  Surgery 2001; 130:636-644.

37.  Zervos EE, Badgwell BD, Abdessalam SF, Farrar WB, Walker MJ, Yee LD, Burak WE Jr.  Selective sentinel lymph node analysis in breast cancer.  Am J Surg. 2001 Oct;182(4):372-6.

38.  Abdessalam SF, Zervos EE, Prasad M, Farrar WB, Yee LD, Walker MJ, Carson WB, Burak WB.  Predictors of positive axillary lymph nodes following sentinel lymph node biopsy in breast cancer.  Am J Surg. 2001 Oct;182(4):316-20.

39.  Nakagawa H, Nuovo GJ, Zervos E, Martin EW, Salovaara Reijo, Aaltonen LA, delaChapelle A.  Age related hypermethylation of MLH1 5’ region in normal colonic mucosa is associated with microsatellite- unstable colorectal cancer development.  Cancer Research 61:6991-6995, 2001.

40.  Zervos EE, Burak WB, Jr.  Lymphatic Mapping in Solid Neoplasms: State of the Art.   Cancer Control 2002 May-Jun;9(3):189-202. Review

41.  Rosemurgy AS, Bloomston M, Zervos EE, Goode SE, Pencev D, Zweibel B, Black TJ.  Transjugular Intrahepatic Portosystemic Shunt versus H-Graft Portacaval Shunt in the Management of Bleeding Varices:  A Cost-Benefit Analysis. Curr Surg 1998; 55: 171-2.

42.  Bloomston M, Shafii AS, Zervos E, Rosemurgy AS.  Timp-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis.  J Surg Res. 2002 Jan; 102(1):39-44.

43.  Bloomston M, Shafii A, Zervos E, Rojiani A, Rosemurgy AS.MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer.  J Surg Res. 2002 Jan; 102(1):35-8.

44.  Haq M, Shafii A, Zervos E, Rosemurgy AS.  In vitro and in vivo matrix metalloproteinase production by pancreatic cancer cells and by distant organs.  Int J Surg Investig. 2000;1(6):459-65.

45.  Burak WB, Hollenbeck S, Zervos E, Yee LD, Young D.  Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg. 2002 Jan; 183(1):23-7.

46.  Bloomston, MB, Zervos, EE, Rosemurgy, AS.  Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.  Ann Surg Oncol. 2002 Aug-Sep;9(7):668-74.

47.  Desai, D, Zervos, EE, Arnold, M.W., Burak, W, Mantil, J, Martin, EW.  Positron emission tomography affects surgical management in recurrent colorectal cancer patients.
Ann Surg Oncol. 2003 Jan-Feb;10(1):59-64.

48.  Bloomston M, Binitie O, Fraiji E, Murr M, Zervos E, Goldin S, Kudryk B, Zwiebel B, Black T, Fargher S, Rosemurgy AS. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 2002 Sep;68(9):827-31

49.  Bloomston M, Durkin A, Yang I, Enkeman S, Rojiani M, Yeatman T, Rosemurgy AS and Zervos EE.  Identification of Molecular Markers for Pancreatic Neuroendocrine Tumors by Genetic Profiling of Core Biopsies.  Ann Surg Oncol. 2004 Apr;11(4):413-9.

50.  Zervos EE, Rosemurgy AS, Al-Saif O, Durkin AJ.Surgical Management of Early Stage Pancreatic Carcinoma.  Cancer Control, January/February 2004; 11:23-31.

51.  Durkin AJ, Bloomston PM, Giarelli N,  Yeatman TJ, Rosemurgy AS, Zervos EE.  Differential expression of the tie-2 receptor and its ligands in pancreatic carcinoma.  Surgical Forum Volume LIV, 2003.

52.  Rosemurgy AS, Zervos EE.  Management of variceal hemorrhage.  Curr Probl Surg. 2003 Jun;40(6):263-343. Review.

53.  Durkin AJ, Bloomston M, Yeatman TJ, Gilbert-Barness E, Cojita D, Rosemurgy AS, Zervos EE.  Differential expression of the Tie-2 receptor and its ligands in human pancreatic tumors. J Am Coll Surg. 2004 Nov;199(5):724-31.

54.  Badgwell BD, Povoski SP, Abdessalam SF, Young DC, Farrar WB, Walker MJ, Yee LD,
       Zervos EE, Carson WE 3rd, Burak WE Jr.  Patterns of recurrence after sentinel lymph node            biopsy for breast cancer. Ann Surg Oncol. 2003 May-Jun;10(4):376-80.

55.  Durkin AJ, Bloomston PM, Rosemurgy AS, Giarelli N, Cojita D, Yeatman TJ, Zervos EE. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am  J Surg. 2003 Nov;186(5):431-6.

56.  Fraiji E Jr, Bloomston M, Carey L, Zervos E, Goldin S, Banasiak M, Wallace M, Rosemurgy AS.    Laparoscopic management of symptomatic achalasia associated with epiphrenic diverticulum.  Surg Endosc. 2003 Oct; 17(10):1600-3. Epub 2003 Jul 21.

57.  Rosemurgy AS, Zervos EE, Bloomston M, Durkin AJ, Clark WC, Goff S.  Post-shunt resource   consumption favors small-diameter prosthetic H-graft portacaval shunt over TIPS for patients Ann Surg. 2003 Jun;237(6):820-5; discussion 825-7.

58.  Zervos EE, Durkin AJ.  Differential gene expression of the Tie-2 receptor and its ligands in human   pancreatic tumors.  J Am Coll Sur 2004; 199:724-731.

59.  Durkin AJ, Korkolis D, Al-Saif O, Zervos EE.  Full-term gestation and transvaginal delivery after wide resection of an abdominal desmoid tumor during pregnancy. J Surg Oncol. 2005 Feb 1;89(2):86-90.

60.   Zervos EE, Pearson H, Durkin AJ, Thometz D, Rosemurgy P, Kelley S, Rosemurgy AS.  In-Continuity Hepatic Resection for Advanced Hilar Cholangiocarcinoma: Survival and Complications.  Am J Surg  2004; 188: 584-588.

61.  Rosemurgy AS, Zervos EE, Clark WC, Thometz DP, Black TJ, Zwiebel BR, Kudryk BT, Grundy LS, Carey LC.TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial. Ann Surg. 2004 Jun;239(6):883-9; discussion 889-91.

62.  Rosemurgy AS, Thometz DP, Zervos EE.  Portal blood flow, effective hepatic blood flow, and outcome after partial portal decompression. J Surg Res. 2004 Mar;117(1):64-70.

63.  Kelley ST, Bloomston M, Serafini F, Carey LC, Karl RC, Zervos E, Goldin S, Rosemurgy P, Rosemurgy AS. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg. 2004 Sep;70(9):743-8; discussion 748-9.

64.  Osborne, D, Boe B, Rosemurgy AS, Zervos EE.  20mm laparoscopic cholecystectomy: fewer ports results in less pain, shorter hospitalization and faster return to normal activity.  Am Surg  2005; 71: 298-302.

65.  Keeling, WB, Osborne D, Luckey, N, Rakita, S. Zervos, EE. Bleeding gastric varices and a mesenteric fibroma in a gravida patient.  Surgical Rounds 29(2); 2006:

66.  Zervos, EE, Osborne, D, Boe, B. Luzardo, G, Rosemurgy, AS.  Prognostic Significance of New Onset Ascites in Patients with Pancreatic Cancer.  W. J Surg Onc. 2006 Mar 28;4:16.

67.  Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, Carey LC, Rosemurgy AS. Staging systems do not accurately predict survival in hilar cholangiocarcinoma: promoting an aggressive operative approach. American Journal of Surgery, Am J Surg. 2005 Nov;190(5):810-5.

68.  Rakita S, Bloomston M, Villadolid D, Thometz D, Zervos E, Rosemurgy A.  Esophagotomy during laparoscopic Heller myotomy cannot be predicted by preoperative therapies and does not influence long-term outcome.  J Gastrointest Surg. 2005 Feb;9(2):159-64.

69.  Rosemurgy AS, Bloomston M, Clark WC, Thometz DP, Zervos EE.  H-graft portacaval shunts versus TIPS: ten-year follow-up of a randomized trial with comparison to predicted survivals. Ann Surg. 2005 Feb;241(2):238-46

70.  Zervos, EE, Osborne, DA, Boe, BA, Rosemurgy, AS.  Mortality following shunting for complicated portal hypertension is dependant upon hospital volume for surgical but not radiological procedures: review of a statewide database.  J GI Surg (submitted).

71.  Bloomston M, Shafii A, Zervos E, Rosemurgy AS, TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo. Am J Surg. 2005 Jun;189(6):675-9.

72. D'Alessio MJ, Rakita S, Bloomston M, Chambers CM, Zervos EE, Goldin SB, Poklepovic J, Boyce HW, Rosemurgy AS.  Esophagography predicts favorable outcomes  after laparoscopic Nissen fundoplication for patients with esophageal dysmotility.  J Am  Coll Surg. 2005 Sep;201(3):335-42.

73. Korkolis, DP, Osborne, D., Boe, BA, Al-Saif, O., Gonzalvo, A., Carey, LC, Rosemurgy, AS, Zervos, EE.  Lymphoepithelial cyst of the pancreas in a young woman.  Surg Rounds  29(1); 2006:21-25.

74. Zervos, EE, Tanner, SM, Osborne, DA, Bloomston PM, Rosemurgy, AS, Ellison, EC, Melvin, WS., delaChapelle, A.   Differential gene expression in patients genetically predisposed to pancreatic cancer.  J Surg Res. 2006 Oct;135(2):317-22. Epub 2006 Jun 30.

75. Durkin, AJ, Osborne, D, Yeatman, TJ, Rosemurgy AS, Armstrong, C., Attkisson, L., Zervos, EE.  EGF receptor antagonism inhibits cellular growth and provides a survival benefit in a murine model of pancreatic adenocarcinoma. J Surg Res 2006 Sep; 135(1): 195-201.  Epub 2006 May 6.

76. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, Yeatman TJ, Carey L, Duhaine L, Kvols LK. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Ann Surg Oncol. 2006 Apr;13(4):572-81. Epub 2006 Feb 28.

77. Durkin, AJ, P. Bloomston, PM,  Giarelli, NB, Rosemurgy , AS, Zervos, EE.   Intraoperative Portal Vein Color Flow Doppler Predicts Outcome Following Small  Diameter Prosthetic H-graft Portacaval Shunt,  Int J Ultrasonography (submitted).

78. Rosemurgy AS, Osborne D, Zervos EE.  Portal hypertension: the role of shunting procedures.Adv Surg. 2005;39:315-29.

79. Zervos, EE, Alexander, G., Osborne, D., Rosemurgy, AS.  Participation in Experimental Protocols for Pancreatic Cancer Confers No Survival Disadvantage Regardless of Therapeutic Strategy Employed.  Ann Surg Onc (submitted).

80. Osborne D, Pappas E, Alexander G, Boe B, Cantor AB, Rosemurgy AS, Zervos EE.  A complication free course ensures a survival advantage in patients after regional therapy for metastatic colorectal cancer.  Am Surg. 2006 Jun;72(6):505-510.

81. S. Cowgill, S. Al-Saadi, D. Villadolid, E. Zervos, A. Rosemurgy II.  Does Barrett's esophagus impact outcome after laparoscopic Nissen fundoplication? Am J Surg. 2006 Nov;192(5):622-6.

82. Cowgill, E. Carey, D. Villadolid, S. Al-Saadi, E. Zervos, A. Rosemurgy Preshunt liver function remains the prominent determinant of survival after portasystemic shunting.  The American Journal of Surgery, Volume 192, Issue 5, Pages 617-621 S.

83. Osborne DA, Alexander G, Boe B, Zervos EE. Laparoscopic cholecystectomy: past, present, and future.Surg Technol Int. 2006;15:81-5.

84. Cowgill SM, Thometz D, Clark W, Villadolid D, Carey E, Pinkas D, Zervos E, Rosemurgy A 2nd.  Conventional Predictors of Survival Poorly Predict and Significantly Underpredict Survival after H-graft Portacaval Shunts. J Gastrointest Surg. 2007 Jan;11(1):89-94. 

85. Rosemurgy AS, Molloy DL, Thometz DP, Villadolid DV, Cowgill SM, Zervos EE. TIPS in Florida: is its application a result of evidence-based medicine? J Am Coll Surg. 2007 May;204(5):794-801; discussion 801-2. Epub 2007 Mar 26. PMID: 17481486 [PubMed - in process]

86. Rosemurgy A, Thometz D, Clark W, Villadolid D, Carey E, Pinkas D, Rakita S, Zervos E.Survival and Variceal Rehemorrhage After Shunting Support Small-Diameter Prosthetic H-graft Portacaval Shunt.J Gastrointest Surg. 2007 Mar;11(3):325-32.

87. D'Alessio ML, Thometz D, Boe BA, Villadolid DV, Zervos EE, Rosemurgy AS. Transduodenal Excision of Ampullary Polyp with Biliopancreatic Sphincteroplasty. Ann Surg Oncol 2007 Jun 27;

88. Goldin SB, Bradner MW, Zervos EE, Rosemurgy AS 2nd. Assessment of pancreatic neoplasms: review of biopsy techniques.J Gastrointest Surg. 2007 Jun;11(6):783-90.

89. Rosemurgy AS, Molloy DL, Thometz DP, Villadolid DV, Cowgill SM, Zervos EE. TIPS in Florida: is its application a result of evidence-based medicine?J Am Coll Surg. 2007 May;204(5):794-801; discussion 801-2. Epub 2007 Mar 26.

Published Motion Pictures

1. D'Alessio ML, Thometz D, Boe BA, Villadolid DV, Zervos EE, Rosemurgy AS. Transduodenal Excision of Ampullary Polyp with Biliopancreatic Sphincteroplasty.Ann Surg Oncol. 2007 Jun 27;

Presentations:
1.  Victor Vaughn Medical Historical Society, Ann Arbor, MI February 2, 1992.
Title:  The University of Michigan Old Main Hospital: A Cultural Icon for Nearly Seven Decades.

2.  University of Michigan AOA Induction Ceremony Keynote Address, Ann Arbor, MI April  1992.
Title:  The University of Michigan Old Main Hospital: A Cultural Icon for Nearly Seven  Decades

3.  American College of Surgeons Florida Committee on Trauma, St. Petersburg, FL, July, 1994.
Title: Oral vs. Parenteral Administration of Fluconazole in Critically Ill Trauma Patients: A Study Comparing Routes of Administration.

4.  American College of Surgeons, Region IV Resident Paper Competition, Nasheville, TN November, 1994.
Title:  Oral vs. Parenteral Administration of Fluconazole in Critically Ill Trauma Patients: A Study Comparing Routes of Administration.

5.  Florida Surgical Society, Tampa, FL, August 18-20, 1995. 
Title: Fluconazole Increases the Bactericidal Activity of Neutrophils.

6.  American College of Surgeons Florida Committee on Trauma, Orlando, FL, July, 1995.
Title:  Fluconazole Increases the Bactericidal Activity of Neutrophils.

7.  Ninth Annual Meeting of the Eastern Association for the Surgery of Trauma, Orlando, FL January 10-13, 1996.
Title:  Fluconazole Increases the Bactericidal Activity of Neutrophils.

8.  Annual Meeting of the Southeastern Surgical Society, Tampa, FL, February 2-5, 1996.
Title:  Peritoneovenous Shunts in Patients with Intractable Ascites: Palliation at What  Price?

9.  Twenty Sixth Annual Meeting of the Western Association for the Surgery of Trauma, Grand     Targhee, WY, February 25 - March 2, 1996.
Title:  Fluconazole Increases the Bactericidal Activity of Neutrophils through Non-Cytokine Mediated Pathway.

10. Eleventh Annual SSAT/Ross Residents and Fellows Research Conference, Napa Valley, CA, May   17-18, 1996.
Title:  Matrix Metalloproteinase Blockade Decreases Mortality in an Orthotopic Model of Human Pancreatic Cancer.

11. Annual Meeting of the American Gastroenterological Association, San Francisco, CA, May     19-22, 1996.
Title:  A Prospective, Randomized Trial Comparing TIPS vs. Peritoneovenous Shunts in the Management of Intractable Ascites
Title:  Elevated Protein Kinase C-  Expression is Associated with an Increased Neoplastic Phenotype in Human Pancreatic Cancer Cells.

13. Thirty-seventh Annual Meeting of the Society for Surgery of the Alimentary Tract, San Francisco, CA, May 19-22, 1996.
Title:  Matrix Metalloproteinase Blockade Decreases Mortality in an Orthotopic Model of Human Pancreatic Cancer. 

14. American Society for Bariatric Surgery, Quebec City, Quebec, Canada, June 12, 1996.
Title: Does Adequate Weight Loss Following Bariatric Surgery Predict Staple Line  Failure?  A Prospective Study.
Title: Impact of Bariatric Surgery on Body Image Perception and Sexuality in Morbidly Obese Patients and Their Partners.

16. University of South Florida Surgical Alumni Society, Tampa, FL June 18, 1996.
Title:  Matrix Metalloproteinase Blockade Decreases Mortality in an Orthotopic Model of Human Pancreatic Cancer.

17. Florida Surgical Society, Captiva Island, FL, August 15-18, 1996.
Title: Matrix Metalloproteinase Inhibition Attenuates Human Pancreatic Cancer Growth In-vitro and Decreases Mortality and Tumorigenesis In-vivo.

18. Forty Ninth Annual Meeting Frederick A. Coller Surgical Society, Colorado Springs, CO, October 2-4, 1996
Title: Matrix Metalloproteinase Inhibition Attenuates Human Pancreatic Cancer Growth In-vitro and Decreases Mortality and Tumorigenesis In-vivo.

19. USF Division of Trauma CME Conference, Tampa, FL,  October 18, 1996.
Title:   Trauma Research Protocols: Conception, Design and Execution

20. University of South Florida Department of Surgery Grand Rounds, Tampa, FL, October 19, 1996.
Title:  Systemic Mediators of Hemorrhagic Shock.

21. Annual Meeting of the Society of Abdominal Surgeons, Tampa, FL November 2-4, 1996.
Title: Novel Therapeutic Strategies in the Treatment of Pancreatic Cancer
Title:    Management of the Intractable Ascites in the Cirrhotic Patient

23. Annual Meeting of the American Pancreatic Association, Chicago, IL November, 1996.
Title:    Reduced Tumorigenicity of Pancreatic Cancer with Matrix Metalloproteinase Inhibition.
Title:    Inhibition of post transcription cytokine gene processing proximal in the cytokine cascade minimizes the severity of acute pancreatitis.

25. American College of Surgeons Florida Committee on Trauma, Orlando, FL, November 9, 1996.
Title:  Sublethal Hemorrhage Induces Tolerance to Endotoxic Death.
Title:  Do Anabolic Steroids Improve Outcome In Trauma Patients?: A Placebo Controlled, Prospective, Randomied Trial

27. Annual Meeting of the Association for Academic Surgery, Chicago, IL, November, 1996.
Title: Matrix Metalloproteinase Inhibition Attenuates Human Pancreatic Cancer Growth In-vitro and Decreases Mortality and Tumorigenesis In-vivo.

28. American College of Surgeons, Region IV Resident Paper Competition, Louisville, KY, November 30, 1996.
Title: Sublethal Hemorrhage Induces Tolerance to Endotoxic Death.

29. One Hundred Eighth Annual Meeting of the Southern Surgical Association, Palm Beach FL, December 2-5, 1996.
Title: Differential Effects on Effective Hepatic Blood Flow: A Comparison Between TIPS and Small Diameter H-Graft Portacaval Shunt.

30. Eastern Association for the Surgery of Trauma, Sanibel Island, FL, January 18, 1997.
Title:  Bioavailability of Fluconazole in Burn Patients: A Study Comparing Routes of Administration.

31. Southeastern Surgical Congress, Nashville, TN, February 5, 1997.
Title:   Small Diameter H-Graft Portacaval Shunt Reduced Portal Flow Yet Maintains Effective Hepatic blood Flow.

32. Fifty Eighth Annual Meeting of the Society of University Surgeons, Tampa, FL, February 13, 1997.
Title: Matrix Metalloproteinase Inhibitors in the Treatment of Pancreatic Cancer.

33. Society of University Surgeons Residents Conference, Tampa, FL, February 15, 1997.
Title: Modulation of the Cytokine Response to Sepsis through Sub-lethal hemorrhage is Neither Cytokine Nor Model Specific.
Title: PKC-  antisense oligodeoxynucleotide treatment confers a survival benefit in an orthotopic model of pancreatic cancer.
Title: Do Anabolic Steroids Improve Outcome In Trauma Patients?: A Placebo Controlled, Prospective, Randomied Trial

36. University of South Florida Health Science Center Annual Research Symposium, February 15, 1997.
Title: Conditioning to Hemorrhagic Shock Improves Survival in a Rat Model.

37. Twenty Seventh Annual Meeting of the Western Association for the Surgery of Trauma, Snowbird, UT, March 3, 1997.
Title: Modulation of the Cytokine Response to Sepsis through Sub-lethal hemorrhage is Neither Cytokine Nor Model Specific.

 38. Fifty-third annual Central Surgical Association Annual Meeting, Chicago IL March 7-9, 1997.
Title:  TIPS vs. H-Graft Portacaval Shunt in the Management of Bleeding Varices: A Cost-Benefit Analysis

39. American Association for Cancer Research, Annual Meeting, San Diego, CA, April 11-14, 1997.
Title:  PKC-  antisense oligodeoxynucleotide treatment confers a survival benefit in an orthotopic model of pancreatic cancer.

40. 17 th Annual Meeting of the Surgical Infection Society, Pittsburgh, PA, May 1-3, 1997.
Title: Cytokine activation through sub-lethal hemorrhage is protective against early lethal endotoxic challenge.
 
41. 17 th Annual Meeting of the Surgical Infection Society, Pittsburgh, PA, May 1-3, 1997.
Title: Pancreatic ascites as a powerful inducer of inflammatory cytokines: the role of known vs unknown factors.

42. 21st Annual Meeting of the Association of VA Surgeons, Louisville, KY, May 5-7, 1997.
Title: Immediate and long-term portal hemodynamic consequences of small diameter h-graft portacaval shunt.

43. American Gastroenterological Association, Digestive Disease Week 1997,  Washington, D.C. May 15-21 1997.
Title: Endovascular salvage of the failing TIPS patient.

44. Society for Surgery of the Alimentary Tract, Digestive Disease Week , Washington, D.C. , May 15-21, 1997
Title: Small diameter H-graft portacaval shunt for bleeding esophageal varices: excellent results in over 110 patients.
Title: Pancreatitis confers a survival benefit in an orthotopic model of pancreatic cancer.

46. 31st Annual Meeting of the Pancreas Club, Inc., Bethesda, MD, May 11, 1997
Title: Inhibition of PKC-  through specific antisense therapy confers a survival benefit in an orthotopic pancreatic cancer model.

47. 14th Annual Meeting of the American Society for Bariatric Surgery, Chicago, IL  June 5-7, 1997
Title:   Vertical banded gastroplasty in a patient with multiple personalities: Nuances and complexities of care.
Title:   Outcome following bariatric surgery in super vs. morbidly obese patients: does weight matter?

49. Fifty Seventh Annual Meeting of the American Association for the Surgery of Trauma, Waikoloa, Hawaii, Sept. 23-28, 1997
Title: Conditioning to Hemorrhagic Shock Improves Survival in a Rat Model

50. 101st Annual Meeting of the Frederick C. Coller Surgical Society, Lake of the Ozarks, MO, October 9-12, 1997
Title: Achieving Tolerance to Hemorrhagic Shock in Rats through Repeat Serial , sublethal Hemorrhage

51. 83rd Annual Clinical Congress, American College of Surgeons, Surgical Forum, Chicago, IL Oct. 12-16, 1997
Title: Conditioning to hemorrhagic shock improves survival and attenuates inflammatory cytokine gene induction in the lung, liver and spleen of rats

52. 91st Annual Scientific Assembly, Southern Medical Association, Charlotte, NC, November 6-8, 1997
Title: Further Application of Advanced Laparoscopy in the 90's: An alternative for failed anti-reflux surgery

53. 22nd Annual Hepatobiliary/Pancreatic Surgery Symposium, Tampa, FL November 9, 1997
Title: Cirrhosis and its complications: a surgeon’s perspective

54. University of South Florida Department of Surgery Grand Rounds, December 19, 1997
Title: Renal vein thrombosis in a transplanted kidney: presentation, diagnosis and management.

55. Twenty Eighth Annual Meeting of the Western Trauma Association, February 21-26, 1998, Lake Louise, Alberta, Canada
Title: Do anabolic steroids improve outcome in trauma patients?  A prospective, randomized trial.

56. Annual Meeting of the Southeastern Surgical Congress, Atlanta, GA, February 2-4, 1998.
Title: Quality of life and anti-reflux medication use following laparoscopic Nissen fundoplication

57. Annual Meeting of the Society of University Surgeons, Milwaukee, WI, February, 1998.
Title: Directed antisense therapy confirms the role of pkc-alpha in the tumorigenicity of pancreatic cancer

58. 22nd Annual Meeting of the Association of VA Surgeons, Baltimore, MD, April 26-28, 1998
Title:  Matrix metalloproteinase inhibition selectively decreases MMP-2 activity in a murine model of pancreatic cancer

59. 32nd Annual Meeting of the Pancreas Club, Inc.  New Orleans, LA, May 19, 1998
Title:   Matrix metalloproteinases in pancreatic cancer:  effects of differentiation on activity in vitro and in vivo.

60.  Annual Meeting of the American Gastroenterological Association, New Orleans, LA, May 21, 1998
Title:   Matrix metalloproteinases in pancreatic cancer:  effects of differentiation on activity in vitro and in vivo.

61.  44 th Clinical Meeting of the Frederick A. Coller Surgical Society, Williamsburg, VA Oct. 1-4, 1998
Title:  Metalloproteinase inhibition in pancreatic cancer reduces both production and activity of MMP-2.

62. Annual Meeting of the Association for Academic Surgery, Seattle, WA, Nov.22, 1998
Title:  Matrix metalloproteinase inhibition supresse MMP-2 activity and activation of PANC-1 cells in vitro.

63. Annual Meeting of the Pancreas Club Inc.,  Orlando, FL May, 1999.
Title: Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prologs survival in a murine model of human pancreatic cancer.

64.  Annual Meeting of the Association for Academic Surgery, Philadelphia, PA November 20, 1999.
Title: Overexpression of TIMP-1 in human pancreatic cancer cells reduces in vitro invasion and reduces in vivo tumor growth.

65.  Annual  Meeting of the Society of Surgical Oncology, New Orleans, LA, March 1999.
Title:    Localizing the sentinel node outside the specialty center, success of the lymphatic mapping course in disseminating new technology.

66. American Liver Foundation Gulf Coast Chapter: Latest strategies and management of liver disease 2000. 
Title:  Management of intractable ascites

67. Society of Surgical Oncology, 53rd Annual Cancer Symposium, New Orleans, LA March 16-19, 2000.
Title:  Localizing the senitinel node outside of the specialty center: success of the lymphatic mapping course in disseminating new technology. 

68. 47th Annual Meeting of the Society of Nuclear Medicine, St. Louis, MO  June 3-7,2000
Title:  Localization of recurrent colorectal cancer using FDG:  correlation between PET and intraoperative beta and gamma probe

69. 34th Annual Meeting of the Association for Academic Surgery, Tampa, FL, November 2-4, 2000.
Title:  FDG-Pet Guided Surgery for Recurrent Colorectal Cancer: A Feasibility Study

70. University of South Florida College of Medicine Department of Surgery Grand Rounds, Nov. 3, 2000.
Title:  Bulls and Buckeyes:  Sentinel Contributions to Radio Guided Surgery
 
71. 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas. December 6-9, 2000.
Title:  Physiologic and Socioeconomic Consequences of Breast Cancer Surgery:  A comparison between sentinel lymphadenectomy and axillary dissection
Title:  Predictive value of the sentinel lymph node in breast cancer:  how many sentinel nodes are enough?

72. Central Surgical Association, Tucson Arizona March 2001
Title:  FDG-PET as an adjunct to CEA in the management of patients with presumed recurrent colorectal cancer and normal radiologic workup.

73. American Society of Breast Surgeons, Second annual meeting, La Jolla, CA May 4-6, 2001
Title:  Selective sentinel lymph node analysis: potential for resource savings.

74. Cleveland Clinic Foundation, Minimally Invasive Approaches in Breast Cancer, June 8, 2001.
Invited guest speaker
Title:  Technical Aspects of Lymphatic Mapping in Breast Cancer

75. Annual Clinical Congress of the American College of Surgeons, New Orleans, LA  October 2001 – Post Graduate Course #10
Title:  Management of Medically Refractory Ascites

76. 55th Annual Cancer Symposium – Society of Surgical Oncology – Denver, CO March 14-17, 2002
 Title: Optimization

 

77. Pancreas Club, Inc – 36th Annual Meeting – May 19th, 2002 – San Francisco, CA
 Title:  TIMP-1 Expression and Angiogenesis in Pancreatic Cancer
 Title:  Differential Gene Expression in Familial Pancreatic Cancer

78. Society for Surgery of the Alimentary Tract – Digestive Disease Week 2002 – San Francisco, CA
 Title:  Differential Gene Expression in Pancreatic Cancer Detected by Representational      Difference Analysis

79. The Florida Chapter of the American College of Surgeons – 2002 Annual Meeting
 Title:  Medically Refractory Ascites

80. Annual Meeting of the Association for Academic Surgery – Boston, MA November 7-9, 2002
 Title:  Response to Cox-2 inhibition independent of Cox-2  Expression in Pancreatic  Cancer

81. Society of Surgical Oncology – Annual Cancer Symposium, March 5-9, 2003, Los Angeles, CA
 Title:  Identification of Molecular Markers for Pancreatic Neuroendocrine Tumors by  Genetic Profiling of Core Biopsies

82. Annual Meeting of the Association of VA Surgeons – Nashville Tennessee, May 3-5, 2003
 Title:  Inhibition of EGF receptor by Novel Tyrosine Kinase Inhibitor produces cell death  in Pancreatic Ductal Adenocarcinoma

83. Annual Meeting of the Society for Surgery of the Alimentary Tract, Orlando, FL May 2003
 Title:  Intraoperative Color Flow Doppler Ultrasound Measurements of Portal Blood  Flow  Predict Outcomes Following Small Diameter Prosthetic H-graft Portacaval Shunts  (HGPCS)

84. Annual meeting of the Pancreas Club, Inc.  Orlando, FL  May 18, 2003.
 Title: Differential Expression of the Tie-2 receptor and its Ligands in Human Pancreatic  Tumors.

85. Surgical Forum Program at the 89th Annual Clinical Congress Meeting of the American College of Surgeons, October 19-23, 2003, in Chicago, Illinois. 
 Title:  Differential Expression of the Tie-2 receptor and its Ligands in Human Pancreatic  Tumors.

86. 18th Annual General Surgery Forum – Steamboat Springs Colorado.  USF Department of Surgery.  Management of Breast Cancer / Management of Liver Tumors.

87. Ohio State University Department of Surgery – General Surgery Forum: Marco Island Florida 2/7-2/9 2004.   Minimally invasive endocrine surgery / Advances in Pancreatic Surgery.

88. Society of Surgical Oncology – Annual Cancer Symposium, March 15-17, 2004, New York, NY.
 Title:  Laparoscopic Resection of Zuckerkandl Pheochromocytoma

89.  Annual Meeting of the Association of VA Surgeons, Richmond, VA  April 27, 2004. 
  Title:  In-Continuity Hepatic Resection for Advanced Hilar Cholangiocarcinoma:  Survival and Complications

90.  Annual Meeting of the Association of VA Surgeons, Richmond, VA  April 27, 2004. 
  Title:  Gene Expression Profiling in Patients with Familial Pancreatic Cancer Identifies  Significant Differentially Regulated Genes

91.  Annual meeting of the Pancreas Club, Inc., New Orleans, LA May 19, 2004.
  Title:  EGF Receptor Antagonism Produces Cell Death and an in vivo Survival Benefit in  a Murine Model of Pancreatic Ductal Adenocarcinoma

92.  World Congress of International Hepato-Pancreato-Biliary Association:  June 2-6,2004,     Washington, D.C. USA;
  Title:  Survival benefit associated with hepatic artery infusion chemotherapy dependent   on numbers of cycles completed and independent of clinical risk indices.

93. Frederick Hicken Symposium – Association of Abdominal Surgeons:  Tampa, FL   Novermber  7, 2004
 Title:  Gall Bladder Cancer
 Title:  Surgical Management of Early Stage Pancreatic Cancer

94.    38th Annual meeting of the Association for Academic Surgery:  Houston, TX November 12,   2004
 Title:  egf receptor antagonism inhibits in vivo angiogenesis and produces a    survival benefit in pancreatic adenocarcinoma

95.   58th Annual meeting of the Society of Surgical Oncology:  Atlanta, GA  March 4, 2005
 Title:  Improved survival with cytoreduction vs. embolization for symptomatic metastic  neuroendocrine tumors.

96.  Southeastern Surgcal Congress,  New Orleans Louisiana, February xx, 2005: 
Title:  20mm laparoscopic cholecystectomy:  Fewer ports result in less pain, shorter hospitalization and faster recovery. 

97.  Association of VA surgeons: 29th annual surgical symposium –
 Title:  Prognostic significance of new onset ascites in patients with pancreatic cancer.

98. Association of VA surgeons: 29th annual surgical symposium                                                                        Title:  Stage does not predict survival after resection of Katskin tumors promotin and  aggressive operative approach.

99. American Hepato Pancreatico Biliary Association Annual Meeting,  Hollywood Florida  April 2005
 Title:  Mortality following shunting for complicated portal hypertension is dependant  upon hospital volume for surgical but not radiological procedures: review of a statewide  database.

100.   2005 Annual Meeting of the American College of Surgeons, San Francisco, CA, October  2005.
 Title:  Management of  Malignant Ascites, Post Graduate Course #16.

101.  Annual Meeting of the Frederick A. Coller Surgical Society, Santa Barbara, CA October  19, 2005.
 Title:  Mortality following shunting for complicated portal hypertension is dependant  upon hospital volume for surgical but not radiological procedures: review of a statewide  database.

102.    Southeastern Surgical Congress, Annual Scientific Meeting.  February 18-21, 2006.   Orlando, FL.
 Title:  A complication free course ensures a survival advantage in patients receiving  regional chemotherapy for metastatic colorectal cancer.

103.   Society of Surgical Oncology Annual Cancer Symposium, March 23-26, San Diego, CA
 Title:  Participation in Experimental Protocols for Pancreatic Cancer Confers No Survival  Disadvantage Regardless of Therapeutic Strategy Employed

104. Society of Surgical Oncology 60th Annual Cancer Symposium, March 15-18,   Washington, D.C. experience

105. AHPBA Las Vegas, NV May 2007 (3 presentations)
 Title:  Outcome following resection for pancreatic cancer based on surgeon experience:  the long and short of it.
 Title:  Tumor lysate-pulsed dendritic cells confer protective immunity in a murine  pancreatic cancer model
 Title:  Frequency with Which Surgeons Undertake Pancreaticoduodenectomy Continues  to Determine Length of Stay, Hospital Charges, and In-hospital Mortality

106. Annual Meeting of the Association of VA Surgeons, Little Rock, AR , May 10,2007.
 Title: Tumor lysate pulsed dendritic cells confer a survival advantage in a murine model  of pancreatic carcinoma.
 Title:  Excellent result following laparoscopic Nissen fundoplication in a single  institution: an analysis of 824 consecutive cases.

107. Annual meeting of the Pancreas Club, Inc.  Washington, DC May 20, 2007. 
 Title:  DC based vaccinations confers protective immunity in a murine model of  pancreatic cancer.
 

Positions Held:
2004-2007:   Councilor at Large:  Frederick A. Coller Surgical Society, University of Michigan
Program Committee
Audit Committee
2005-2008:  Faculty Council University of South Florida College of Medicine
Committee on Committees
Nominating Committee
2006-2009: Medical Student Selection Committee - University of South Florida College of  Medicine
2006-present:  Chair, Search Committte, Division Chief Trauma and Emergency Surgery
University of South Florida
2006-present:  Search Committee Member, Associate Dean for Clinical Research, University of  South Florida
2006-present:  Cell Therapies Advisory Committee – Moffitt Cancer Center, Tampa, FL
2005-present:  Member at Large, Faculty Council, University of South Florida College of     Medicine.
2006-2007: Patient Satisfaction Subcommittee, Dean’s Leadership Council
2006-2007: Dean’s Leadership Council - University of South Florida
2002- 2005: Program Director:  Tampa Bay Surgical Society
2002- present: Surgical Suites Committee – Tampa General Hospital
2003- present:  Director of Surgical Research, Department of Surgery, University of South    Florida
2003- present:  Director, GI Oncology Tumor Board, Tampa General Hospital
2002-present: Health information management committee – Tampa General Hospital
2001- present: Course Director: Non-resectional approaches in the management of colorectal    liver metastases.   University of South Florida College of Medicine

Invited Presentations:
Tampa General Healthcare Community Outreach Program – 9/23/06 Tampa Florida – Pancreatic Cancer

University of South Florida Department of Internal Medicine – Grand Rounds 10/26/06 – Pancreatic Cancer

Association for Academic Surgery – Career development conference, Chicago, IL October 7, 2006.  Reviewing the Medical Literature

The Ohio State University,  Annual Radioguided Surgery Course,  March 2001
Invited Guest speaker
Title:  Minimally Invasive Radioguided Parathyroidectomy

Cleveland Clinic Foundation, Minimally Invasive Approaches in Breast Cancer, June 8, 2001.
Invited guest speaker
Title:  Technical Aspects of Lymphatic Mapping in Breast Cancer

James Cancer Hospital, GI tumor Update, April 18, 2003
Invited guest speaker
Title:  Surgical therapy for early stage pancreatic cancer

Florida Chapter of the American College of Surgeons:  The Human Genome Project

Key Biscayne Florida  July 2003

University of South Florida Department of Surgery 13th Annual General Surgery Forum:   Update on Breast Cancer;  Current Management of Colorectal Liver Metastases;   Steamboat Springs, CO  January 2004

The Ohio State University – General Surgery Forum  Marco Island Florida 2/04

The Ohio State University – Advances in Pancreatic Disease – Chronic Pancreatitis 9/04 Columbus, OH.

ACS 91st Annual Clinical Congress, General Session:  Mangagement of Cirrhotic and Malignant Ascites, San Francisco, CA.  October 2005.

15th Annual General Surgery Forum:  University of South Florida Department of Surgery – Copper Mountain Colorade, January 16-21, 2006.
Update on Breast Cancer 2006, Current management of metastic colorectal cancer,  hepatocellular carcinoma, intrahepatic cholangiocarcinoma

Published Abstracts:

1. Bass, SS, Zervos, EE, Sweeney, JF, Ko, F, Robson, MC, Rosemurgy, AS.  Fluconazole increases bactericidal activity of neutrophils.  J Trauma 39:1212, 1995.

2. Zervos, EE, Goode, SE, Wright, T, Rosemurgy, AS.  A prospective randomized trial comparing TIPS and peritoneovenous shunt in the treatment of intractable ascites.  Gastroenterology 110: A1368, April 1996.

3. Zervos, EE, Robson, MC, Rosemurgy, AS.  Fluconazole increases bactericidal activity of neutrophils without activation of the cytokine cascade.  J Trauma 41:10-4, 1996.

4. Franz, MG, Zevos, EE, Fink, GW, Norman, JG, Rosemurgy, AS.  Matrix metalloproteinase blockade decreases mortality in an orthotopic model of human pancreatic cancer.  Gastroenterology 110:A1386, April 1996.

5. Gower, WR, Franz, MG, Norman, JG, Fabri, PJ, Rosemurgy, AS, Zervos, M.  Elevated protein kinase C-  expression is associated with an increased neoplastic phenotype in human pancreatic cancer cells.  Gastroenterology 110: A522, April 1996.

6. Zervos, EE, Norman, JG, Gower, W, Watkins, D, Rosemurgy, AS.  Reduced Tumorgenicity of pancreatic cancer with matrix metalloproteinase inhibition.  Pancreas 13:462, 1996.

7. Zervos, EE, Fink, GW, Norman, JG, Robson, MC, Rosemurgy, AS.  Fluconazole increases bactericidal activity of neutrophils through non-cytokine mediated pathway.  Journal of Infection: Index and Reviews, Vol IV, p 14, 1996.

8. Zervos, EE, Bass, SS, Robson, MC, Rosemurgy, AS.  Fluconazole increases bactericidal activity of neutrophils.  Journal of Infection: Index and Reviews, Vol IV, p 14, 1996.

9. Denham, DW, Rosemurgy, AS, Zervos, EE, Franz, M, Dean, NM, Gower, W.  PKC-  antisense oligodeoxynucleotide treatment confers a survival benefit in an orthotopic model of pancreatic cancer.  Proceedings of the American Association for Cancer Research, 38: 421, #2819, 1997.

10. Bloomston, PM, Zervos, EE, Goode, SE, Rosemurgy, AS.  Outcomes following bariatric surgery in super vs. Morbidly obese patients: Does weight matter?  Obesity Surgery 7:109,1997.

11. Bloomston, PM, Zervos, EE, Goode, SE, Rosemurgy, AS.  Vertical banded gastroplasty in a patient with multiple personalities: Nuances and complexities of care.  Obesity Surgery 7:114, 1997.

12. Camps, M, Zervos, E, Goode, S, Rosemurgy, AS.  Sexuality Study.  Obesity Surgery 6: 110, 1997.

13. Camps, M, Goode, S, Zervos, E, Rosemurgy, AS.  Staple-line integrity study.  Obesity Surgery 6: 119, 1997.

14. Zervos, E, Norman, J, Watkins, D, Rosemurgy, AS.  Modulation of cytokine response to sepsis through sublethal hemorrhage is neither cytokine nor model specific.  J Trauma 42:157, 1997.

15. Zervos, EE, Goode, SE, Rosemurgy, AS.  Further application of advanced laparoscopy in the 1990's: An Alternative for failed anti-reflux surgery.  Southern Medical Journal 90: s123, 1997.

16. Denham, W. , Fink G, Jang JG, Zervos, EE, Norman JG. Inhibition of post transcription cytokine gene processing proximal in the cytokine cascade minimizes the severity of acute pancreatitis. Pancreas 13:433, 1996.

17. Zervos, EE, Murphy, CM, Zwiebel, B, Black, TJ, Rosemurgy, AS.  Endovascular salvage of the failing TIPS patient.  Gastroenterology, 112: A1424, 1997.

18. Rosemurgy, AS, Serafini, FM, Zervos, EE, Goode, SE.  Small diameter H-graft portacaval shunt for bleeding esophageal varices: excellent results in over 110 patients.  Gastroenterology 112: A1469,  1997.

19. Denham, DW, Zervos, EE, Franz, MG, Rosemurgy, AS, Norman, JG.  Pancreatitis confers a survival benefit in an orthotopic model of pancreatic cancer.  Gastroenterology 112: A1437,1997.

20. Shafii, AE, Zervos, EE, Rosemurgy, AS.  Matrix metalloproteinases in pancreatic cancer:  effects of differentiation on activity in vitro and in vivo.  Gastroenterology 114: A497, 1998.

21. Serafini, F., Goode, S., Zervos, E, et al.  Renal hemodynamics and function after partial portal decompression.  Gastroenterology 114: A1339, 1998.

22. Shafii, AE, Zervos, EE, Rosemurgy, AS. Matrix metalloproteinases in pancreatic cancer:  effects of differentiation on activity in vitro and in vivo.  Gastroenterology,  114: A1425, 1998.

23. Rosemurgy AS, Bloomston M, Zervos EE, Goode SE, Pencev D, Zweibel B, Black TJ. Transjugular Intrahepatic Portosystemic Shunt versus H-Graft Portacaval Shunt in the Management of Bleeding Varices: A Cost-Benefit Analysis. Gut: Key Studies for Evidence-Based Clinical Care. Abstraction from Surgery Oct 1997; 1998;122: 794-800.

24. Rosemurgy AS, Bloomston M, Zervos EE, Goode SE, Pencev D, Zweibel B, Black TJ. Transjugular Intrahepatic Portosystemic Shunt versus H-Graft Portacaval Shunt in the Management of Bleeding Varices: A Cost-Benefit Analysis. NHS Centre for Reviews and Dissemination 1999.

25. Bloomston M, Durkin A, Rosemurgy A, Yeatman  T, Zervos E.  :  Identification of Molecular Markers for Pancreatic Neuroendocrine Tumors by Genetic  Profiling of Core Biopsies.  Annals of Surgical Oncology 2003; 10: s8 (4).

26. Zervos, E, Rosemurgy AS, Durkin AJ, Korkolis D, Alsaif O, Pappas E, Rakita S.  Survival benefit associated with hepatic arterial chemotherapy dependent on number of cycles completed and independent of clinical risk indices.  HPB Journal 2004; 6:16 #57.

27. Durkin, AJ, Rosemurgy AS, Hodul P, Yeatman TJ, Cojita D, Shields DW, Zervos EE.  EGF Receptor Antagonism Inhibits In vivo angiogenesis and produces a survival benefit in pancreatic adenocarcinoma.  J Surg Res  2004; 121: 279.

28. Rosemurgy AS, Bloomston M, Zervos EE.  Transjugular intrahepatic portosystemic  shunt is not more cost effective than HGPCS.  Gut 43(1): 11. July 1998.

29. Kramer AA, Zervos EE, Gooede SE, et al.  Do anabolic steroids improve outcome in  trauma patients? A double blind placebo controlle prospective randomized clinical trial.   Journal of Trauma Injury, Infection and Critical Care 44(2):425, February 1998.

30. Bloomston M., Rosemurgy AS,  Zhou J, Zervos EE, Yeatman T.  Large scale proteomic analysis to identify serum markers for pancreatic cancer.  Ann Surg Onc  12(2): S25, 2005.

31. Rosemurgy AS, Clark WC, Carey EK, Zervos, EE..  Long term outcome witn nonselective partial portal decompression for portal hypertension encourages application.  J GI Surg 9 (4): 31, p 532, 2005.

32. Osborne DA, Boe BB, Rosemurgy AS, Zervos EE.  Mortality following portal decompression for bleeding varices dependent on hospital volume for surgical but not radiologic shunts.  J GI Surg 9 (4): 32, p 533, 2005.

33. Vohra, N., Pilon-Thomas, S., Osborne, D., Rosemurgy, AS., Mulé, J., Zervos, E.  Tumor  lysate pulsed dendritic cells provide protective immunity in a murine pancreatic cancer  model.  Ann Surg Onc (supplement) 14(2): 154, p.78, 2007.

34, Hernandez, J., Cowgill, S., Collins, A., Al-Saadi, S., Ross, S., Cooper, J., Zervos, E.,  Rosemurgy, A.S.  CA 19-9 velocity predicts disease free survival and overall survival  after pancreatectomy of curative intent.  Ann Surg Onc (supplement) 14(2): 217, p.96,  2007.

35. Cowgill, S., Al-Saadi, S., Villadolid, D., Kraemer, E., Shapiro, M., Mullinax, J., Cooper,  J., Goldin, S., Zervos, E., Rosemurgy, AS. Aggressive approach to extrahepatic  cholangiocarcinomas warranted because margin status and stage do not impact survival  after resection. Ann Surg Onc (supplement) 14(2): 218, p.97, 2007.

Books Edited:
Handbook of Surgical Oncology
Publisher:  Pocket Medicine.Com
2004
Editors:  Emmanuel E. Zervos, M.D., Steven B. Goldin, M.D.

Book Chapters:
Rosemurgy AS, Osborne D, Zervos EE.  Portal hypertension: the role of shunting procedures.  Adv Surg. 2005;39:315-29.

Zervos, EE, Rosemurgy, AS.  Small Diameter H-Graft Portacaval Shunt vs. TIPS for Portal Hypertension.  In:  Cameron, J, ed.  Advances in Surgery.  St. Louis: Mosby, 1997: 105-126.

Zervos, EE, Rosemurgy, AS.  Partial Shunts. In: Sarfeh, IJ, ed. Problems in General Surgery: Portal Hypertension.  Partial Shunts.  Philadelphia: Lippincott, Williams and Wilkins, 1998: 113-123.

Rosemurgy AS, Zervos EE:  Management of Bleeding Esophageal Varices.  Current Problems in Surgery, in press.

Rosemurgy AS, Zervos EE:  Surgical Treatment of Portal Hypertension.  Current Surgical Therapy, Ed. John Cameron;  2003.

Zervos EE, Carey LC.  Hepatic Malignancy.  South Florida Handbook of Surgical Oncology

Zervos EE, Rosemurgy AS.  Portal Hypertension in Textbook of Surgery.  Ed:  Miller 2004.

Gallagher SH, Zervos EE, Murr MM.  Distal Pancreatectomy for Tumor.  Pancreatic Cancer Ed:  Evans, Hruban, Von Hoff.  Jones and Bartlett Publishers.

Zervos EE, Rosemurgy AS.  Portal Hypertension.  Advances in Surgery.


Grant Support:

Principal Investigator: National Institutes of Health, National Cancer Institute  R21 CA115018-01 A1 2006-2008; "A phase II study on direct tumor injection of TNFerade followed by KLH-pulsed autologous dendritic cells in patients with unresectable pancreatic cancer"
$673,150.00 awarded

University of South Florida Department of Surgery Young Investigator’s Award - $75,000.00

University of South Florida Dean’s Office Young Faculty Support Grant - $200,000

Frederick A. Coller Surgical Society Research Support Grant – 2002 - $10,000.00


Grants Pending:

Industry Sponsored Support:

A Randomized Trial Comparing 5-Fluoroacil, External Beam Radiation, and Gemcitabine With or Without 32P Radiopharmaceutical Therapy as First Line Therapy in Patients With Locally/Regionally Advanced Non-Resectable Pancreatic Cancer.
Sponsor:  University of South Florida
Role:  Co-Investigator
$500,000

A Phase II Multi-Center, Single Arm Evaluation of Preoperative Chemoradiation Plus TNFerade™ Biologic (AgGVegr.tnf.11D) Prior to Esophagectomy For Locally Advanced Resectable Esophageal Cancer.
Sponsor:  Genvec, Inc.
Role:  Co-Investigator

An open-label, phase I, dose-escalation study of Tumor Necrosis Factor gene transfer-α (TNFerade™ Biologic) with radiation therapy for locally advanced, recurrent, or metastatic solid tumors.
Sponsor:  Genvec, Inc.
Role:  Co-Investigator

A Randomized Placebo Controlled Study of OSI-774 (Tarceva™) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Sponsor:  OSI Pharmaceuticals
Role: Site Principal Investigator

A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Anti-TNFα Monoclonal Antibody (Infliximab) to Treat Cancer-related Cachexia in Subjects with Pancreatic Cancer.
Sponsor:  Centocor, Inc
Role:  Co-Investigator

A Multicentre, Randomised, Double-Blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects with Severe Acute Necrotizing Pancreatitis.
Sponsor:  Astra-Zeneca, Inc.
Role:  Co-Investigator

A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Ertapenem Sodium (MK – 0826) Versus Cefotetan for the Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery.
Sponsor:  Merck, Inc.
Role:  Co-Investigator

A phase II clinical trial of Genexol-PM in patients with advanced pancreatic cancer.
Sponsor:  Samyang Corporation
Role: Site Principal Investigator
Amount: $103,580.00